Fragment 176-191 vs AOD-9604: Are They the Same Thing?
Here is how these two compounds compare — based on published research, not marketing claims.
Fragment 176-191
17
Indexed Studies
Animal Studies
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
AOD-9604
20
Indexed Studies
Animal Studies
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
PSI OVERVIEW
Here is the key difference between these compounds and what it means for the research.
This is one of the most confused comparisons in the peptide world. Fragment 176-191 is the original fat-burning region of human growth hormone (amino acids 176-191). AOD-9604 is a modified version of that same fragment with a tyrosine residue addition. They target the same biological pathway. The key fact: AOD-9604 went to Phase IIb clinical trials for obesity and failed to demonstrate statistically significant weight loss.
Key Differences
| Attribute | Fragment 176-191 | AOD-9604 |
|---|---|---|
| Evidence Level | Animal Studies | Animal Studies |
| Category | HGH Fragment | Modified HGH Fragment |
| Human Data | Minimal. A few small studies. No completed clinical trials for obesity. | One Phase IIb trial that failed its primary obesity endpoint. Small supportive studies. |
| Safety Profile | Very limited safety data. Theoretical safety profile is favorable since it lacks the growth-promoting effects of full HGH. | Phase IIb trial showed no serious safety concerns. Generally well-tolerated but efficacy was not demonstrated. |
| Key Limitations | Very limited evidence. No pivotal trial data. Stability and bioavailability challenges. | Clinical development for obesity was discontinued after the failed trial. |
Mechanism Comparison
HOW THEY WORK
These compounds work through different biological pathways. Here is how each one operates at the cellular level.
Fragment 176-191
The lipolytic (fat-burning) region of human growth hormone, isolated from the rest of the molecule. Stimulates fat breakdown without the growth-promoting or glucose-disrupting effects of full HGH.
AOD-9604
Fragment 176-191 with a tyrosine residue added to improve stability. Same lipolytic mechanism — stimulates fat breakdown and inhibits fat formation without growth or glucose effects.
Nearly identical. Both target the same fat-metabolism pathway — the lipolytic region of growth hormone. AOD-9604 adds a tyrosine residue for improved stability, but the core mechanism is the same. The difference is structural stability, not mechanism of action.
Research Evidence
RESEARCH EVIDENCE
Between these compounds, researchers have published over 37 indexed studies. Here are the key findings.
Both L2. AOD-9604 has slightly more clinical data because it reached Phase IIb — but that trial failed. Fragment 176-191 has less formal clinical data. Neither has demonstrated weight loss efficacy in controlled human trials.
For fat metabolism research, both target the same pathway.
For evidence of clinical efficacy, neither has demonstrated significant weight loss in humans.
For stability, AOD-9604's modification may provide better bioavailability.
For honest assessment: both remain popular in peptide therapy despite lacking efficacy data.
Key Limitations
- •AOD-9604 failed its pivotal obesity trial.
- •Fragment 176-191 has never reached pivotal clinical trials.
- •The popularity of both compounds in peptide therapy exceeds their evidence base.
- •Comparing two compounds that both lack efficacy data has limited clinical utility.
PSI Verdict
SUPPORTED BY EVIDENCE
Both stimulate lipolysis in preclinical models through the growth hormone fragment pathway. AOD-9604's Phase IIb trial confirmed safety at tested doses. The lipolytic mechanism is pharmacologically plausible.
NOT YET ESTABLISHED
Neither has demonstrated clinically meaningful weight loss in controlled human trials. AOD-9604's pivotal trial failed its primary endpoint. Fragment 176-191 has not been tested in a pivotal trial.
CONFIDENCE LEVEL
Low for both as weight management tools. The mechanism is interesting. The human evidence is not there. If someone is choosing between these two, the more important question is whether either has the evidence to support the intended use — and currently, neither does.
Community Discussion
WHAT THE COMMUNITY IS SAYING
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Fragment 176-191
"Fragment 176-191 is a cheaper alternative to AOD-9604"Misleading comparison
"Fragment 176-191 burns fat without side effects"Insufficient evidence
AOD-9604
"AOD-9604 burns fat without affecting muscle"Plausible but modest effect
"AOD-9604 helps with joint pain too"Insufficient evidence
Safety Comparison
SAFETY PROFILE
What is currently known about the safety of each compound based on available research.
Fragment 176-191
Very limited safety data. Theoretical safety profile is favorable since it lacks the growth-promoting effects of full HGH.
AOD-9604
Phase IIb trial showed no serious safety concerns. Generally well-tolerated but efficacy was not demonstrated.
Both appear safe based on limited data. AOD-9604 has more formal safety data from its Phase IIb trial. Neither has serious safety concerns, but neither has extensive long-term monitoring data either.
WHAT THE RESEARCH SUGGESTS
These are essentially the same compound with a minor structural modification. Neither has proven effective for weight loss in humans. Their continued popularity is driven by theoretical mechanism and accessibility, not clinical evidence.
Frequently Asked Questions
Explore Each Compound
For the full evidence profile, PSI Verdict, and indexed research data, visit each compound's dedicated page.
Looking for a physician experienced with peptide therapy?
Every physician in the PSI directory is individually verified for active licensure, board certification, and clinical peptide experience.
Browse the PSI Physician Directory →Explore Individual Research Pages
Related PSI Resources
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.